Sign In
Buy STOK
$29.46
+0.780 (+2.72%)
At Close: Jun 03, 2026
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates
07:00am, Thursday, 07'th Aug 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
04:30pm, Wednesday, 06'th Aug 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
11:06am, Wednesday, 30'th Jul 2025
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 16'th Jul 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 17'th Jun 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics: Impressive Pipeline And Big Backers
11:27pm, Sunday, 15'th Jun 2025
Stoke Therapeutics is pioneering RNA-based therapies, with a lead candidate for Dravet Syndrome aiming for true disease modification, unlike current symptom-focused treatments. The company's pipeline
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference
07:30am, Thursday, 29'th May 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet
11:01am, Friday, 16'th May 2025
The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
10:50am, Tuesday, 13'th May 2025
Stoke Therapeutics, Inc. (STOK) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.57 per share a year
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
07:00am, Tuesday, 13'th May 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:05am, Monday, 28'th Apr 2025
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Tuesday, 22'nd Apr 2025
Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
